Rafael Pharmaceuticals Reaches Milestone of 25 Active Sites for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy